michael schumacher, mona, david kelly, we'll have more coverage throughout the hour as we get ready for fed chair jerome powell to host what will actually be a virtual press conference at 2:30 p.m >> all right, kelly. the other big story of the day, some positive results coming out of a trial of gilead's coronavirus drug, remdesivir it's helping to boost the markets in a big way today and meg terrell has the details. hi, meg. >> hi, tyler these were the results we were waiting for from a nih study a double-blind of remdesivir, the gold standard. we were not expecting these results for another month, but we got them today from dr. anthony fauci in an oval office briefing in just a little time ago. he told us this in this trial of more than a thousand hospitalized patients, they saw a 31% faster time to recovery for those on the drug, about 15 days taking remdesivir versus about 11 for placebo he also described a suggested survival benefit 8% of those on the drug passed away versus 11.6% of those on placebo. and he called it suggested, because it wasn't yet statistically significant. "the